Catheter Ablation and Rate Control of Atrial Fibrillation in Patients With Heart Failure
Catheter Ablation Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure: A Multicenter Study
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Drum Tower Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- age>18 years
- documented atrial fibrillation
- New York Heart Association Ⅱ-Ⅳ or left ventricular ejection fraction <50%
Exclusion Criteria:
- heart failure that had a suspected reversible cause
- previous ablation
- any contraindication to catheter ablation
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
catheter ablation group
atrial fibrillation patients with heart failure who received catheter ablation for rhythm control
|
|
rate control group
atrial fibrillation patients with heart failure who received pharmacological approaches for rate control
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Major adverse cardiac events
Time Frame: up to 3 years
|
composite of all-cause mortality, stroke and unplanned hospitalization due to cardiovascular reasons
|
up to 3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
all-cause mortality
Time Frame: up to 3 years
|
up to 3 years
|
|
|
stroke
Time Frame: up to 3 years
|
stroke must be certified by CT scan
|
up to 3 years
|
|
unplanned hospitalization due to cardiovascular reasons
Time Frame: up to 3 years
|
Unplanned hospitalization will be present only if the patient is hospitalized unexpectedly because of persisting or increasing complaints of heart failure and ventricular arrhythmias
|
up to 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jin Geng, MD, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Study Chair: Bingjian Wang, MD, Huai'an first people's hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20160020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.